Global Observational Cohort Study on the Prediction of Unwanted Adverse Effects in Individuals Infected With Chronic Hepatitis C Receiving a Long Acting Interferon Plus Ribavirin.

Trial Profile

Global Observational Cohort Study on the Prediction of Unwanted Adverse Effects in Individuals Infected With Chronic Hepatitis C Receiving a Long Acting Interferon Plus Ribavirin.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Aug 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Interferons
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GUARD-C
  • Sponsors Roche
  • Most Recent Events

    • 24 Apr 2013 Recruitment completion is expected on 30 Sep 2013 according to the Iranian Registry of Clinical Trials.
    • 01 Nov 2012 Planned number of patients changed from 3000 to 4450 as reported by ClinicalTrials.gov.
    • 01 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top